Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years

Abstract The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xi Zhang, Xiaocui An, Lei Shi, Xueliang Yang, Yunru Chen, Xiaojing Liu, Jianzhou Li, Feng Ye, Shumei Lin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4823ce3bbcea4fac9f181ecf35b25772
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4823ce3bbcea4fac9f181ecf35b25772
record_format	dspace
spelling	oai:doaj.org-article:4823ce3bbcea4fac9f181ecf35b257722021-12-02T16:31:57ZBaseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years10.1038/s41598-021-92757-02045-2322https://doaj.org/article/4823ce3bbcea4fac9f181ecf35b257722021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92757-0https://doaj.org/toc/2045-2322Abstract The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-seven chronic hepatitis B patients treated with entecavir for 10 years were enrolled in this study. Liver function, quantitative anti-hepatitis B core, hepatitis B surface and e antigens, HBV DNA and RNA were measured at baseline and each follow-up. Virological response was defined as double-negative HBV DNA and RNA; serological response was defined as hepatitis B e antigen seroconversion. After antiviral therapy, quantitative anti-hepatitis B core showed an overall downward trend. Patients with virological response had significantly higher quantitative anti-hepatitis B core levels than those without virological response at baseline. Patients with serological response also had higher quantitative anti-hepatitis B core levels than those without serological response at baseline and week 24. Baseline quantitative anti-hepatitis B core level was the only independent predictor for virological and serological responses. Baseline quantitative anti-hepatitis B core level was powerfully predictive of double-negative HBV DNA and RNA in chronic hepatitis B patients receiving long-term entecavir therapy.Xi ZhangXiaocui AnLei ShiXueliang YangYunru ChenXiaojing LiuJianzhou LiFeng YeShumei LinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xi Zhang Xiaocui An Lei Shi Xueliang Yang Yunru Chen Xiaojing Liu Jianzhou Li Feng Ye Shumei Lin Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
description	Abstract The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-seven chronic hepatitis B patients treated with entecavir for 10 years were enrolled in this study. Liver function, quantitative anti-hepatitis B core, hepatitis B surface and e antigens, HBV DNA and RNA were measured at baseline and each follow-up. Virological response was defined as double-negative HBV DNA and RNA; serological response was defined as hepatitis B e antigen seroconversion. After antiviral therapy, quantitative anti-hepatitis B core showed an overall downward trend. Patients with virological response had significantly higher quantitative anti-hepatitis B core levels than those without virological response at baseline. Patients with serological response also had higher quantitative anti-hepatitis B core levels than those without serological response at baseline and week 24. Baseline quantitative anti-hepatitis B core level was the only independent predictor for virological and serological responses. Baseline quantitative anti-hepatitis B core level was powerfully predictive of double-negative HBV DNA and RNA in chronic hepatitis B patients receiving long-term entecavir therapy.
format	article
author	Xi Zhang Xiaocui An Lei Shi Xueliang Yang Yunru Chen Xiaojing Liu Jianzhou Li Feng Ye Shumei Lin
author_facet	Xi Zhang Xiaocui An Lei Shi Xueliang Yang Yunru Chen Xiaojing Liu Jianzhou Li Feng Ye Shumei Lin
author_sort	Xi Zhang
title	Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
title_short	Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
title_full	Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
title_fullStr	Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
title_full_unstemmed	Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
title_sort	baseline quantitative hbcab strongly predicts undetectable hbv dna and rna in chronic hepatitis b patients treated with entecavir for 10 years
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4823ce3bbcea4fac9f181ecf35b25772
work_keys_str_mv	AT xizhang baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT xiaocuian baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT leishi baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT xueliangyang baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT yunruchen baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT xiaojingliu baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT jianzhouli baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT fengye baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years AT shumeilin baselinequantitativehbcabstronglypredictsundetectablehbvdnaandrnainchronichepatitisbpatientstreatedwithentecavirfor10years
_version_	1718383807249252352

Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years

Ejemplares similares